Kyle Doherty

The FDA has accepted a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in R/R LBCL.

Lung cancer experts convened at an OncLive® Scientific Interchange and Workshop to discuss treatment sequencing in HER2+ NSCLC.

Alicia Morgans, MD, MPH, discusses findings from ARACOG trial of the cognitive effects of darolutamide vs enzalutamide in prostate cancer.

External validation of a circulating immune protein signature model confirmed its prognostic value for OS in recurrent ovarian cancer.

Experts in lung cancer gathered at an OncLive® Scientific Interchange and Workshop during the 2026 ASCO Annual Meeting to discuss HER2-mutated NSCLC.

Fred Saad, MD, CQ, FRCS, FCAHS, discusses data from subgroup analyses of the PSMAddition trial by disease volume and in de novo/recurrent mHSPC.

Cadonilimab plus axitinib demonstrated an ORR of 51.6% and manageable safety in frontline advanced nccRCC.

The FDA has approved adjuvant belzutifan plus pembrolizumab for patients with ccRCC at intermediate-high or high risk of recurrence.

Baseline ctDNA positivity was associated with inferior DFS regardless of treatment arm in the phase 3 KEYNOTE-564 trial.

Alexander Kutikov, MD, FACS, discusses the role of focal therapy in RCC management.

Pavlos Msaouel, MD, PhD, discusses a study of panitumumab-based EGFR blockade in SMARCB1-deficient RMC.

FDA approved generic gallium Ga 68 gozetotide injection for PET imaging of PSMA-positive lesions in prostate cancer.

ASCO 2026 genitourinary experts unpack key prostate and bladder cancer data, revealing practice-changing takeaways and what they mean for patient care.

Aglatimagene besadenovec plus ERBT displayed an accumulating benefit in high-risk prostate cancer after extended follow-up.

Long-term follow-up data showed ePLND significantly reduces the risk of metastasis in ISUP GG 3-5 prostate cancer with radical prostatectomy.

The FDA will review data for adjuvant giredestrant in ER-positive, HER2-negative early-stage breast cancer after positive iDFS data from LidERA.

Dato-DXd led to benefits in terms of TFST, PFS2, and TSST vs chemotherapy in frontline TNBC.

OncLive spoke with urothelial cancer experts during Bladder Cancer Awareness Month to understand the current and future treatment landscape.

Prespecified biomarker analyses of ASCENT-03 and ASCENT-04 showed longer PFS with sacituzumab govitecan–based regimens vs comparators in TNBC.

Abemaciclib markedly improved PFS vs placebo in patients with advanced dedifferentiated liposarcoma.

Adjuvant durvalumab plus tremelimumab significantly improved DFS vs active monitoring in both high- and intermediate-risk resected RCC.

Amivantamab plus lazertinib led to a median OS of 41.0 months in EGFR-mutated advanced NSCLC.

Nicholas Zorko, MD, PhD, discusses B7-H3 targeting in lung, GU, and gynecologic malignancies.

OncLive spoke with experts in the field of GU oncology to gain their insights on the most notable presentations from the 2026 AUA Annual Meeting.

The FDA priority review of neladalkib for TKI-pretreated ALK-positive NSCLC is supported by data from the phase 1/2 ALKOVE-1 trial.

The CHMP granted a positive opinion to perioperative pembrolizumab/enfortumab vedotin as well as pembrolizumab and berahyaluronidase alfa in MIBC.

Matthew Galsky, MD, discusses the present and future treatment landscape of MIBC during Bladder Cancer Awareness Month.

GU experts identified key abstracts of interest from the upcoming ASCO Annual Meeting via OncLive’s social media.

Ahead of the 2026 AUA Annual Meeting, GU cancer experts highlighted the abstracts that they are anticipating the most.

Perioperative durvalumab plus EV showed positive topline efficacy findings in MIBC.